138 related articles for article (PubMed ID: 15627892)
21. Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients.
Villena V; López-Encuentra A; Echave-Sustaeta J; Martín-Escribano P; Ortuño-de-Solo B; Estenoz-Alfaro J
Cancer; 1996 Aug; 78(4):736-40. PubMed ID: 8756365
[TBL] [Abstract][Full Text] [Related]
22. CEA and CA 549 in serum and pleural fluid of patients with pleural effusion.
Hernández L; Espasa A; Fernández C; Candela A; Martín C; Romero S
Lung Cancer; 2002 Apr; 36(1):83-9. PubMed ID: 11891038
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of two strategies for the interpretation of tumour markers in pleural effusions.
Trapé J; Sant F; Franquesa J; Montesinos J; Arnau A; Sala M; Bernadich O; Martín E; Perich D; Pérez C; Lopez J; Ros S; Esteve E; Pérez R; Aligué J; Gurt G; Catot S; Domenech M; Bosch J; Badal JM; Bonet M; Molina R; Ordeig J
Respir Res; 2017 May; 18(1):103. PubMed ID: 28545517
[TBL] [Abstract][Full Text] [Related]
24. Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions.
Li CS; Cheng BC; Ge W; Gao JF
Int J Clin Pract; 2007 Mar; 61(3):444-8. PubMed ID: 17313612
[TBL] [Abstract][Full Text] [Related]
25. [Tumor markers in the diagnosis of ascitic and pleural puncture fluids].
Mezger J; Lamerz R; Arnholdt H; Huhn D; Wilmanns W
Onkologie; 1986 Feb; 9(1):11-6. PubMed ID: 3523341
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic value of CA 549 in pleural fluid. Comparison with CEA, CA 15.3 and CA 72.4.
Villena V; López-Encuentra A; Echave-Sustaeta J; Martín-Escribano P; Ortuño-de-Solo B; Estenoz-Alfaro J
Lung Cancer; 2003 Jun; 40(3):289-94. PubMed ID: 12781427
[TBL] [Abstract][Full Text] [Related]
27. Tumor markers in pleural effusions.
Topolcan O; Holubec L; Polivkova V; Svobodova S; Pesek M; Treska V; Safranek J; Hajek T; Bartunek L; Rousarova M; Finek J
Anticancer Res; 2007; 27(4A):1921-4. PubMed ID: 17649796
[TBL] [Abstract][Full Text] [Related]
28. [Tumor markers in the assessment of malignant and benign pericardial effusion].
Karatolios K; Maisch B; Pankuweit S
Herz; 2011 Jun; 36(4):290-5. PubMed ID: 21491120
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions.
Miédougé M; Rouzaud P; Salama G; Pujazon MC; Vincent C; Mauduyt MA; Reyre J; Carles P; Serre G
Br J Cancer; 1999 Nov; 81(6):1059-65. PubMed ID: 10576665
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions.
Passebosc-Faure K; Li G; Lambert C; Cottier M; Gentil-Perret A; Fournel P; Pérol M; Genin C
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6862-7. PubMed ID: 16203775
[TBL] [Abstract][Full Text] [Related]
31. The diagnostic usefulness of tumour markers CEA and CA-125 in pleural effusion.
Sthaneshwar P; Yap SF; Jayaram G
Malays J Pathol; 2002 Jun; 24(1):53-8. PubMed ID: 16329556
[TBL] [Abstract][Full Text] [Related]
32. Tumor-associated trypsin inhibitor (TATI) in pleural effusions.
Rapellino M; Pecchio F; Baldi S; Adamo MR; Macri M; Ricardi G
Scand J Clin Lab Invest Suppl; 1991; 207():47-9. PubMed ID: 1780690
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma.
Huang WW; Tsao SM; Lai CL; Su CC; Tseng CE
Pathology; 2010 Apr; 42(3):224-8. PubMed ID: 20350214
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic performance of CD66c in lung adenocarcinoma-associated malignant pleural effusion: comparison with CEA, CA 19-9, and CYFRA 21-1.
Son SM; Han HS; An JY; Choe KH; Lee KM; Lee KH; Kim SS; Lee YM; Lee HC; Song HG; Lee OJ
Pathology; 2015 Feb; 47(2):123-9. PubMed ID: 25551300
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic Accuracy of Tumor Markers CYFRA21-1 and CA125 in the Differential Diagnosis of Ascites.
Trapé J; Gurt G; Franquesa J; Montesinos J; Arnau A; Sala M; Sant F; Casado E; Ordeig JM; Bergos C; Vida F; Sort P; Isava Á; González M; Molina R
Anticancer Res; 2015 Oct; 35(10):5655-60. PubMed ID: 26408739
[TBL] [Abstract][Full Text] [Related]
36. Assessment of a panel of tumor markers for the differential diagnosis of benign and malignant effusions by well-based reverse phase protein array.
Braunschweig T; Chung JY; Choi CH; Cho H; Chen QR; Xie R; Perry C; Khan J; Hewitt SM
Diagn Pathol; 2015 May; 10():53. PubMed ID: 26022333
[TBL] [Abstract][Full Text] [Related]
37. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
Elia S; Massoud R; Guggino G; Cristino B; Cortese C; De Massimi AR; Zenobi R
Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic Accuracy of CYFRA21-1 in the Differential Diagnosis of Pleural Effusions.
Trapé J; Sant F; Montesinos J; Arnau A; Sala M; Bernadich O; Martín E; Perich D; Lopez J; Ros S; Esteve-Valverde E; Pérez R; González-Fernández C; Aligue J; Catot S; Domenech M; Ruiz D; Bonet M; Molina R; Ordeig J
Anticancer Res; 2019 Sep; 39(9):5071-5076. PubMed ID: 31519617
[TBL] [Abstract][Full Text] [Related]
39. New approaches in the diagnostic procedure of malignant pleural effusions.
Terracciano D; Di Carlo A; Papa P; Cicalese M; Maietta P; Cecere C; Mariano A; Macchia V
Oncol Rep; 2004 Jul; 12(1):79-83. PubMed ID: 15201963
[TBL] [Abstract][Full Text] [Related]
40. CEA, AFP and CA 19-9 analysis in peritoneal fluid to differentiate causes of ascites formation.
Kaleta EJ; Tolan NV; Ness KA; O'Kane D; Algeciras-Schimnich A
Clin Biochem; 2013 Jun; 46(9):814-8. PubMed ID: 23454392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
